专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20120022126A1 Method Of Treating Diabetes Mellitus 审中-公开
标题翻译：治疗糖尿病的方法
公开(公告)号：US20120022126A1
公开(公告)日：2012-01-26
申请号：US13193990
申请日：2011-07-29
申请人： Seng H. Cheng , Nelson S. Yew , Ronald K. Scheule , Hongmei Zhao
发明人： Seng H. Cheng , Nelson S. Yew , Ronald K. Scheule , Hongmei Zhao
IPC分类号： A61K31/4025 , A61P7/00 , A61P13/12 , A61P3/08
CPC分类号： A61K31/4025 , A61K31/395 , A61K31/40 , Y10S514/866
摘要： The invention provides methods of treating a diabetic subject comprising administering a glucosylceramide synthase inhibitor to the subject.
摘要翻译：本发明提供治疗糖尿病受试者的方法，包括向受试者施用葡萄糖神经酰胺合酶抑制剂。

12. 发明授权

US08003617B2 Methods of treating diabetes mellitus 有权
标题翻译：治疗糖尿病的方法
公开(公告)号：US08003617B2
公开(公告)日：2011-08-23
申请号：US11667224
申请日：2005-11-09
申请人： Seng H. Cheng , Nelson S. Yew , Ronald K. Scheule , Hongmei Zhao
发明人： Seng H. Cheng , Nelson S. Yew , Ronald K. Scheule , Hongmei Zhao
IPC分类号： A61K31/70 , A61K31/685 , A61K31/535 , A61K31/42 , A61K31/40 , A61K31/195 , A61K31/16 , A61K31/155
CPC分类号： A61K31/4025 , A61K31/395 , A61K31/40 , Y10S514/866
摘要： The invention provides methods of treating a diabetic subject comprising administering a glucosylceramide synthase inhibitor to the subject.
摘要翻译：本发明提供治疗糖尿病受试者的方法，包括向受试者施用葡萄糖神经酰胺合酶抑制剂。

13. 发明申请

US20080161379A1 Methods of Treating Diabetes Mellitus 有权
标题翻译：治疗糖尿病的方法
公开(公告)号：US20080161379A1
公开(公告)日：2008-07-03
申请号：US11667224
申请日：2005-11-11
申请人： Seng H. Cheng , Nelson S. Yew , Ronald K. Scheule , Hongmei Zhao
发明人： Seng H. Cheng , Nelson S. Yew , Ronald K. Scheule , Hongmei Zhao
IPC分类号： A61K31/40 , A61P3/10 , A61K31/16
CPC分类号： A61K31/4025 , A61K31/395 , A61K31/40 , Y10S514/866
摘要： The invention provides methods of treating a diabetic subject comprising administering a glucosylceramide synthase inhibitor to the subject.
摘要翻译：本发明提供治疗糖尿病受试者的方法，包括向受试者施用葡萄糖神经酰胺合酶抑制剂。

14. 发明授权

US06465007B1 Transgene expression in polarized cells 失效
标题翻译：极化细胞中的转基因表达
公开(公告)号：US06465007B1
公开(公告)日：2002-10-15
申请号：US09340509
申请日：1999-07-01
申请人： Simon J. Eastman , Quiming Chu , Jennifer D. Tousignant , Seng H. Cheng , Ronald K. Scheule
发明人： Simon J. Eastman , Quiming Chu , Jennifer D. Tousignant , Seng H. Cheng , Ronald K. Scheule
IPC分类号： A61K4800
CPC分类号： A61K48/0008 , A61K48/00
摘要： The well-differentiated airway epithelium is the principal target tissue for gene therapy for the treatment of CF. However, recent studies have shown that gene delivery vehicles, such as cationic lipid:DNA complexes, can be inefficient at binding to and internalizing into polarized epithelial cells. The present invention provides a method to improve gene therapy by using a compound capable of disrupting tight junctions. In the practice of the invention, the transfection of a biologically active molecule by a cationic amphiphile:biologically active molecule complex or other lipid or viral or nonviral vectors is improved by treating the cells with a class of compounds known in the art as absorption enhancers or tight junction disrupting compounds.
摘要翻译：分化良好的气道上皮是用于治疗CF的基因治疗的主要靶组织。然而，最近的研究已经表明，基因递送载体，例如阳离子脂质：DNA复合物，在与极化上皮细胞结合和内化时可能是低效的。本发明提供一种通过使用能够中断紧密连接的化合物来改善基因治疗的方法。在本发明的实践中，通过阳离子两亲物：生物活性分子复合物或其它脂质或病毒或非病毒载体转染生物活性分子通过用本领域已知的一类化合物作为吸收增强剂或紧密连接的中断化合物。

15. 发明申请

US20090105141A1 INTRAVENTRICULAR PROTEIN DELIVERY FOR AMYOTROPHIC LATERAL SCLEROSIS 审中-公开
标题翻译：宫内膜间质性输卵管造影
公开(公告)号：US20090105141A1
公开(公告)日：2009-04-23
申请号：US12175870
申请日：2008-07-18
申请人： James Dodge , Ronald K. Scheule
发明人： James Dodge , Ronald K. Scheule
IPC分类号： A61K38/18 , A61P25/00
CPC分类号： A61K38/30
摘要： Amyotrophic Lateral Sclerosis can be successfully treated using intraventricular delivery of a neurotrophic growth factor, IGF-1. The administration can be performed slowly to achieve maximum effect. Effects are seen on both sides of the blood-brain barrier, making this a delivery means for Amyotrophic Lateral Sclerosis which affects both brain and skeletal muscle.
摘要翻译：肌营养不良性侧索硬化可以使用神经营养生长因子IGF-1的脑室内输送成功治疗。可以缓慢执行给药以达到最大效果。在血脑屏障的两侧看到效果，这是影响脑和骨骼肌的肌萎缩性侧索硬化的递送手段。

16. 发明申请

US20100216709A1 SYSTEMIC INSULIN-LIKE GROWTH FACTOR-1 THERAPY REDUCES DIABETIC PERIPHERAL NEUROPATHY AND IMPROVES RENAL FUNCTION IN DIABETIC NEPHROPATHY 审中-公开
标题翻译：系统性胰岛素样生长因子-1治疗可减少糖尿病性外周神经病变，改善糖尿病患者的肾功能
公开(公告)号：US20100216709A1
公开(公告)日：2010-08-26
申请号：US12609115
申请日：2009-10-30
申请人： Ronald K. Scheule , Qiuming CHU
发明人： Ronald K. Scheule , Qiuming CHU
IPC分类号： A61K38/30 , A61P25/02 , A61K31/7088
CPC分类号： A61K38/30 , A61K48/00 , C12N15/86 , C12N2750/14143 , C12N2830/008
摘要： The present invention provides methods of treatment of patients suffering from the complications of blood sugar disorders: diabetic peripheral neuropathy and diabetic nephropathy by administration of IGF-1 via protein therapy or gene therapy. It relates to methods of treating an individual having a diabetic disorder or a hyperglycemic disorder, comprising administering to the individual an effective amount of a DNA vector expressing IGF-1Eb or IGF-1Ec in vivo or an effective amount of at the IGF-1Eb or IGF-1Ec protein in the early hyperalgesia stage or in patients that have advanced to the hyposensitivity stage. Treatment at the early hyperalgesia stage prevents subsequent hyposensitivity with increases or maintenance of sensory nerve function. IGF-1Eb or IGF-1Ec treatment also increases muscle mass and improves overall mobility, which indicates a treatment-related improvement in motor function. Treatment with IGF-1Eb or IGF-1Ec at the hyposensitivity stage reverses hyposensitivity and improves muscle mass and overall health. Systemic IGF-1 provides a therapeutic modality for treating hyposensitivity associated with DPN. In addition, IGF-1Eb or IGF-1Ec provides a therapeutic modality for treating diabetic nephropathy. IGF-1Eb or IGF-1Ec improves renal function as evidenced by a modulation in serum albumin concentration and a reduction in urine volume and protein levels. IGF-1Eb or IGF-1Ec also reduces diabetic glomerulosclerosis.
摘要翻译：本发明提供了通过蛋白质治疗或基因治疗施用IGF-1来治疗患有血糖紊乱并发症的患者的糖尿病性周围神经病变和糖尿病性肾病的方法。本发明涉及治疗患有糖尿病病症或高血糖病症的个体的方法，包括向个体施用有效量的体内表达IGF-1Eb或IGF-1Ec的DNA载体或在IGF-1Eb或 IGF-1Ec蛋白在早期痛觉过敏阶段或患有进展至低敏感期的患者。在早期痛觉过敏阶段的治疗可以通过增加或维持感觉神经功能阻止随后的敏感性。 IGF-1Eb或IGF-1Ec治疗也增加肌肉质量并改善整体移动性，这表明运动功能的治疗相关改善。 IGF-1Eb或IGF-1Ec在过敏反应阶段的治疗反转了敏感性，改善了肌肉质量和整体健康。系统性IGF-1提供治疗与DPN相关的敏感性的治疗方式。此外，IGF-1Eb或IGF-1Ec提供治疗糖尿病性肾病的治疗方法。 IGF-1Eb或IGF-1Ec可改善肾功能，如血清白蛋白浓度的调节和尿量和蛋白质水平的降低所证明。 IGF-1Eb或IGF-1Ec还可减少糖尿病肾小球硬化。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式